

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)



(10) International Publication Number
WO 2023/056295 A1

(51) International Patent Classification:

A61P 27/06 (2006.01) A61K 31/7088 (2006.01)
C12N 15/113 (2010.01) C12Q 1/6883 (2018.01)

(21) International Application Number:

PCT/US2022/077176

(22) International Filing Date:

28 September 2022 (28.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/250,492 30 September 2021 (30.09.2021) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **PRAVEEN, Kavita**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **COPPOLA, Giovanni**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **FERREIRA, Manuel Allen Revez**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **GURSKI, Lauren**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SCHURMANN, Claudia**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **LEGAARD, Paul K.** et al.; Armstrong Teasdale LLP, 7700 Forsyth Boulevard, Suite 1800, St. Louis, Missouri 63105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TREATMENT OF GLAUCOMA WITH RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 12 (ARHGEF12) INHIBITORS




Figure 1A

(57) Abstract: The present disclosure provides methods of treating subjects having glaucoma or elevated intraocular pressure (IOP), methods of identifying subjects having an increased risk of developing glaucoma or developing elevated IOP, methods of detecting human Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) variant nucleic acid molecules and variant polypeptides, and ARHGEF12 variant nucleic acid molecules and variant polypeptides.